GlassScriptPhysician profile
Allison S Thomas
NPI 1396315271
$2,340.92
in general payments reported to CMS, 2019-2025
23 companies · $489 in 2025
The $489 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $39.80 · 2022: $254 · 2023: $1,397 · 2024: $161 · 2025: $489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,094 · Travel and Lodging: $953.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,094.16 |
| Travel and Lodging | $953.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Relievant Medsystems, INC. | $1,303.89 | 2023 | Intracept |
| Forte Bio-Pharma LLC | $124.33 | 2024-2025 | Prolate, Nalocet, Tanlor |
| Valinor Pharma, LLC | $100.15 | 2024-2025 | Movantik |
| Janssen Biotech, INC. | $93.62 | 2022-2023 | Tremfya |
| Collegium Pharmaceutical, INC. | $87.18 | 2024-2025 | Xtampza, Belbuca |
| Braeburn INC. | $70.34 | 2025 | Brixadi |
| Scilex Pharmaceuticals INC. | $69.81 | 2024-2025 | |
| Vertex Pharmaceuticals Incorporated | $61.03 | 2025 | |
| Glaxosmithkline, LLC. | $58.41 | 2022-2023 | Shingrix, Trelegy Ellipta |
| Indivior INC. | $56.61 | 2025 | Sublocade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.66 | 2025 | Relistor |
| Abbvie INC. | $41.98 | 2022-2023 | |
| Medtronic, INC. | $33.47 | 2022 | |
| Amarin Pharma, INC. | $26.89 | 2021-2022 | |
| Pfizer INC. | $23.75 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $21.30 | 2022 | |
| Ucb, INC. | $20.67 | 2022 | |
| Lilly USA, LLC | $19.28 | 2023 | Mounjaro |
| Virtus Pharmaceuticals LLC | $17.68 | 2024 | Levorphanol Tartrate |
| Sanofi-Aventis U.S. LLC | $17.21 | 2022 | |
| Biogen, INC. | $15.58 | 2021 | |
| Tonix Medicines, INC. | $14.73 | 2025 | Tonmya |
| Emd Serono, INC. | $14.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.